



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

AZD4320

Cat. No.:	HY-112416
CAS No.:	1357576-48-7
Molecular Formula:	C ₄₅ H ₄₈ ClF ₃ N ₄ O ₇ S ₃
Molecular Weight:	945.53
Target:	Bcl-2 Family
Pathway:	Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (105.76 mM; Need ultrasonic)				
Preparing Stock Solutions	Solvent Concentration Mass				
		1 mg	5 mg	10 mg	
		1 mM	1.0576 mL	5.2880 mL	10.5761 mL
		5 mM	0.2115 mL	1.0576 mL	2.1152 mL
		10 mM	0.1058 mL	0.5288 mL	1.0576 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 6.25 mg/mL (6.61 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC ₅₀ s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.	
IC ₅₀ & Target	BCL2 17 nM (IC ₅₀ , KPUM-UH1 cells)	BCLxL 17 nM (IC ₅₀ , KPUM-UH1 cells)
In Vitro	AZD4320 potently augments the antitumor effect of AZD5153 (Cat. No.: HY-100653A) in double expressing lymphoma (DEL)- and double hit lymphoma (DHL)-derived cell lines in a dose-dependent manner. AZD4320 shows mostly synergistic, and at least additive, growth inhibitory effects on DEL- and DHL derived cell lines, and profoundly increases cells undergoing apoptosis in all three cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

PROTOCOL

Cell Assay ^[1]

Two DEL-derived cell lines, KPUM-MS3 and KPUM-UH1, and a DHL-derived cell line, STR-428 are used. To examine the combinatory growth inhibitory effects of AZD4320, cells are treated with five concentrations (0.25, 0.5, 1.0, 2.0, 4.0×IC₅₀) for 72 h, and subjected to a modified MTT assay^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2023 Sep 19;14(1):5709.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Takimoto-Shimomura T, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2018 Jun 21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA